‘Text/HTML’ of page ‘EAY191-N2 (ComboMATCH): NF1 Mutation in Breast Cancer ‘
Frequently Asked Questions Below, you can find FAQs about clinical research and this particular clinical trial.
Read MoreContent Block Tag: EAY191-N2 (ComboMATCH): NF1 Mutation in Breast Cancer
‘Text/HTML’ of page ‘EAY191-N2 (ComboMATCH): NF1 Mutation in Breast Cancer ‘
Am I eligible for this study? If you are over the age of 18 and have hormone receptor-positive metastatic breast cancer with NF1 mutation, you may be able to participate. Your healthcare team is the best source for information about your treatment options, including cancer clinical trials. Be sure to take this information to your […]
Read More‘Text/HTML’ of page ‘EAY191-N2 (ComboMATCH): NF1 Mutation in Breast Cancer ‘
About This Study This protocol called, EAY191-N2, is part of the ComboMATCH precision medicine initiative for people that have hormone receptor-positive metastatic breast cancer with NF1 mutation. The ComboMATCH registration trial studies show how well treatment that is directed by genetic testing works in treating patients with solid tumors that have spread to nearby […]
Read More‘Text/HTML’ of page ‘EAY191-N2 (ComboMATCH): NF1 Mutation in Breast Cancer ‘
Clinical Studies FAQ
Read More‘Text/HTML’ of page ‘EAY191-N2 (ComboMATCH): NF1 Mutation in Breast Cancer ‘
The EAY191-N2 Study FAQ
Read More